DOCSLIB.ORG

Experience from Rare Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Experience from Rare Diseases AN INDUSTRY PERSPECTIVE ON THE USE OF RWE FOR REGULATORY PURPOSES: EXPERIENCE FROM RARE DISEASES May 7, 2019 Emily S. Brouwer, MPH PharmD PhD Data Sciences Institute, Global Outcomes Research and Epidemiology Shire Pharmaceuticals, now part of Takeda 1 DISCLOSURES • Opinions and views expressed here today are my personal views and do not represent Takeda’s collective view or position, nor do they express the views, position or opinions of other industry stakeholders • Full time employee of Takeda Pharmaceuticals and shareholder 2 | 04/03/2019 WHAT IS THE DEFINITION OF A RARE DISEASE? HOW RARE IS RARE? • United States FDA definition of rare disease1: – Affects < 200,000 persons in the United States – Affects > 200,000 persons but the Maximum 54-65 persons costs will not be recovered for developing product in this stadium with the disease of interest • EU definition of rare disease2: – < 5 per 10,000 Image: Presenter’s own image. • There are > 6,000 rare diseases2 Michigan Stadium Capacity: ~108,000 1FDA. Developing products for rare diseases and conditions. Available at: https://www.fda.gov/industry/developing-products-rare-diseases-conditions. Accessed on: April, 2019 2Antoni Montserrat Moliner and Jaroslaw Waligora. The European Union Policy in the Field of Rare Diseases. Adv Exp Med Bio.. 2017; 1031:561-587. A FEW EXAMPLES OF RARE DISEASE Duchenne Muscular Dystrophy Primary Hereditary Immune Angioedema ~2:100,000 Deficiency persons1 Hunter ~0.62:100,000 Hemophilia male births2 Syndrome Congenital Protein C Deficiency 1Aasia Ghazi and J Andrew Grant. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013; 7: 103-113. 2Raluy-Callado M, et al. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet Journal of Rare Diseases 2013, 8:101. CHALLENGES IN DEVELOPING THERAPEUTICS FOR RARE DISEASE: CURRENT EXPERIENCE AND OPPORTUNITIES FOR USE OF REAL WORLD EVIDENCE (RWE) Natural history of disease often not well characterized Potentially not feasible/unethical to conduct randomized placebo controlled study Challenging to evaluate effectiveness in special populations Rare diseases often have a long diagnostic journey and frequently it is difficult to enroll patients in trials Note: Presenter’s own perspective/experience NATURAL HISTORY STUDIES USING REAL WORLD DATA CAN PROVIDE IMPORTANT INFORMATION ON CLINICAL COURSE OF DISEASE1 • Disease progression • Burden of illness • Standard of care • Background rates of comorbid conditions • Outcomes that are important to the patient, including patient reported outcomes (PROs) 1 Augustine EF et al. Clinical trials in rare disease: challenges and Image 1: Presenter’s own image. Image 2: Obtained from personal friend with permission opportunities. J Child Neurol. 2013; 28(9): 1142-1150. REGISTRIES PROVIDE SOURCE OF DATA FOR NATURAL HISTORY STUDY • Icatibant Outcome Survey (IOS)1 • Hunter Outcome Survey (HOS)2 • Initiated in 2009 as part of a • Initiated in 2005 as part of a commitment to regulatory authorities commitment to regulatory authorities • HAE I/II patients enrolled ➔ Initially • MPS II patients enrolled icatibant only patients but expanded to • In addition to data collected from include patients on C1-esterase normal clinical practice, patients also inhibitors were able to complete a Patient • In addition to data collected from Reported Outcome (HS-FOCUS)* normal clinical practice, IOS also collects • Provides context to newer clinical trial data on HAE attacks, an important data on progression of Hunter clinical outcome that is not captured Syndrome with regularity in existing medical records *HS-FOCUS: Hunter Syndrome - Functional Outcomes for Clinical Understanding Scale • Provides context to newer clinical trial HAE: Hereditary Angioedema data on the progression of HAE disease MPS II: Mucopolysaccharidosis type II 1Longhurst et al. Real-world outcomes in hereditary angioedema: first experience from the icatibant outcomes survey in the United Kingdom. Allergy Asthma Clin Immunol (2018) 14:28. 2Muenzer et al. Ten years of the Hunter Outcomes Survey (HOS): insights acheivements, lessons learned from a global patient registry. Orphanet Journal of Rare Disease. 2017 12:82. LONGITUDINAL COHORT DATA IN PARALLEL TO CLINICAL TRIAL ADDS CONTEXT TO TRIAL DATA1 • Hunter Syndrome longitudinal cohort study conducted in parallel to clinical trial • Patients aged 2-18 years of age with a concomitant medication for Mucopolysaccharidosis type II enrolled (N=55) • Measured the same Patient Reported Outcomes (PRO) as the clinical trial: Differential Abilities Scales®, second edition (DAS-II) and Vineland Adaptive Behavior Scales™, second addition (VABS-II) – Association with the HS-FOCUS that was also collected (PRO used in natural history study) • Evaluated changes in PRO measurements over time 1Yee et al. Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with Hunter syndrome. 15th Annual WORLD Symposium™, February 4–8, 2019, Orlando, FL, USA CHALLENGES IN DEVELOPING A REGISTRY OR A PROSPECTIVE OBSERVATIONAL STUDY FOR REGULATORY PURPOSES • Critical data elements: which elements are able to be collected reliably, are important to patients, and will be relevant data elements to provide context to ongoing clinical trials • Timing of registry: must start early enough in development to have enough data and not compete with developmental studies • Geographical representation: Some countries/sites may have very few patients, if conducting prospective observational study at same time, patient recruitment becomes difficult • Disease registry (vs. product only registry): The optimal type of registry is a disease registry, however, this can be challenging in a competitive landscape • Comparison of patients: patients enrolled in trials are likely to be very different (especially if enrolled concurrently); historical controls may also not be similar due to changes in standard of care Note: Challenges are identified from presenter’s own perspective/experience HISTORICAL CONTROLS HAVE BEEN USED FOR REGULATORY APPROVAL IN RARE DISEASE/CANCER1 Disease Therapy Year Approved Acute hypoammonemia/severe urea cycle disorders sodium phenylacetate and sodium benzoate 2005 Pompe Disease (alpha-glucosidase deficiency) algucosidase alfa 2006 Toxic plasma methotrexate concentrations glucarpidase 2012 Relapsed or refractory Acute Lymphoblastic Leukemia (ALL) blinatumomab 2014 Hypophosphatasia (HPP) asfotase alfa 2015 Lysosomal acid lipase (LAL) deficiency sebelipase alfa 2015 Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) Cerliponase alfa 2017 For the majority of these examples, statistical approaches were not used to compare the single-arm intervention to the historical control Propensity score approaches were used for blinatumomab historical control comparison 1Lim et al. Minimizing patient burden through the use of historical control data in innovative confirmatory trials: review of methods and opportunities. Therapeutic innovation and regulatory science 2018, Vol. 52 (5)546-559. REAL WORLD EVIDENCE USED FOR LABEL EXPANSION TO NEW INDICATIONS AND SPECIAL POPULATIONS IN RARE DISEASE: ECULIZUMAB • Eculizumab pediatric indication for atypical Hemolytic Uremic Syndrome (aHUS)1 • Retrospective registry data of 19 pediatric patients (<18 years of age) supplemented formal clinical trial in this sub-population • Clinical outcomes were nominally compared to pivotal trials, no formal analyses conducted • Extension of eculizumab indication in the EU to patients without history of transfusion2 • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) registry was approved to be used in place of a randomized controlled trial to expand indication 1Soliris® (eculizumab) prescribing information. FDA. November 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf Accessed: April 2019 2European Medicines Agency. Extension of indication variation assessment report: Soliris. February 2015. Available at: https://www.ema.europa.eu/en/documents/variation- report/soliris-h-c-791-ii-0066-epar-assessment-report-variation_en.pdf. Last accessed April 2019. POTENTIAL EXTENSIONS OF REAL WORLD EVIDENCE USE FOR REGULATORY PURPOSES: IDENTIFICATION OF PATIENTS AND DATA ELEMENTS • Patients with rare diseases have a long diagnostic journey and a high misdiagnosis rate1 • It is often difficult to identify patients for inclusion in clinical trials; a situation not uncommon with most rare diseases or select subgroups1 • New methodologies that leverage: electronic medical records, administrative claims, registries, and chart reviews would increase efficiencies of clinical trials and would be able to2: • Improve identification of patients for clinical trials • Confirm surrogate, physician-reported, Patient Reported Outcomes (PROs) and other alternative endpoints from clinical trials • Perform comparative effectiveness studies using linked PROs as co-primary or secondary endpoints 1Blӧβ S, et al. Diagnostic needs for rare diseases and shared prediagnostic phenomena: results of a German-wide expert Delphi survey. PLoS One. 2017: 12(2): e0172532. 2Presenter’s own perspective/experience ELECTRONIC MEDICAL RECORD (EMR) DATA USING NATURAL LANGUAGE PROCESSING + TRADITIONAL CLAIMS ALGORITHMS FOR HAE COHORT IDENTIFICATION1 Both N=84 (65%) HAE: Hereditary Angioedema ICD-9/10: International *Diagnosis code only, n=24; notes only, n=70; classification of disease, 9th, 10th codes and notes,
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 08: Functional Limitations and Disability Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process.
    [Show full text]
  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
    Transaction Drug 1st (DIN) 2nd (PIN) 3rd (PIN) 4th (PIN) 5th (PIN) 6th (PIN) 7th (PIN) 8th (PIN) 9th (PIN) 10th (PIN) 11th (PIN) 12th (PIN) 13th (PIN) Alectinib (Alecensaro®) 02458136 00904400 − − − − − − − − − − − 150 mg capsule Alemtuzumab (LemtradaTM) 02418320 00904161 00904162 00904163 00904164 00904165 00904166 00904167 − − − − − 12 mg / 1.2 mL single-use vial Asfotase alfa (Strensiq®) 02444615 00904483 00904484 00904485 − − − − − − − − − 18 mg / 0.45 mL single-use vial Asfotase alfa (Strensiq®) 02444623 00904486 00904487 00904488 00904489 00904490 − − − − − − − 28 mg / 0.7 mL single-use vial Asfotase alfa (Strensiq®) 02444631 00904491 00904492 00904493 − − − − − − − − − 40 mg / 1 mL single-use vial Asfotase alfa (Strensiq®) 02444658 00904494 00904495 00904496 00904497 00904498 00904499 00904500 00904501 00904502 00904504 00904505 − 80 mg / 0.8 mL single-use vial Canakinumab (Ilaris®) 150 mg/mL powder for solution 02344939 00904404 00903809 00904410 − − − − − − − − − for injection Canakinumab (Ilaris®) 02460351 00904405 00904411 00904412 − − − − − − − − − 150 mg/mL solution for injection Ceftolozane / Tazobactam 02446901 00904433 − − − − − − − − − − − (Zerbaxa®) 1 g / 0.5 g vial Cerliponase Alfa (Brineura®) 150 mg / 5 mL solution for 02484013 00904634 00904635 00904636 − − − − − − − − − intracerebroventricular infusion Cladribine (MavencladTM) 02470179 00904524 00904525 00904526 00904642 − − − − − − − − 10 mg tablet Cysteamine (ProcysbiTM) 02464713 00904354 00904355 − − − − − − − − − − 75 mg delayed-release capsule Daclastavir (DaklinzaTM)
    [Show full text]
  • Sebelipase Alfa) Injection, for Intravenous Use And/Or Antihistamines May Prevent Subsequent Reactions in Those Cases Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------­ • Hypersensitivity Reactions including Anaphylaxis: Observe patients These highlights do not include all the information needed to use during and after the infusion. Consider interrupting the infusion or KANUMA safely and effectively. See full prescribing information lowering the infusion rate, based on the severity of the reaction. If a for KANUMA. severe hypersensitivity reaction occurs, immediately stop the infusion and initiate appropriate treatment. Pre-treatment with antipyretics KANUMA (sebelipase alfa) injection, for intravenous use and/or antihistamines may prevent subsequent reactions in those cases Initial U.S. Approval: 2015 where symptomatic treatment is required. (5.1) • Hypersensitivity to Eggs or Egg Products: Consider the risks and ----------------------------INDICATIONS AND USAGE---------------------­ benefits of treatment in patients with known systemic hypersensitivity KANUMA™ is a hydrolytic lysosomal cholesteryl ester and reactions to eggs or egg products. (5.2) triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency. (1) ------------------------------ADVERSE REACTIONS-------------------------­ The most common adverse reactions are: ----------------------DOSAGE AND ADMINISTRATION-----------------­ Patients with Rapidly Progressive LAL Deficiency Presenting within the • Patients with Rapidly Progressive Disease Presenting within the First 6 First 6 Months of Life: The recommended starting dosage is 1 mg/kg as an Months of Life (≥30%): diarrhea, vomiting, fever, rhinitis, anemia, intravenous infusion once weekly. For patients who do not achieve an cough, nasopharyngitis, and urticaria. (6.1) optimal clinical response, increase to 3 mg/kg once weekly. (2.1) • Pediatric and Adult Patients (≥8%): headache, fever, oropharyngeal Pediatric and Adult Patients with LAL Deficiency: The recommended pain, nasopharyngitis, asthenia, constipation, and nausea.
    [Show full text]
  • 1 LYSOSOMAL ACID LIPASE: from CELLULAR LIPID HANDLER to 2 IMMUNOMETABOLIC TARGET 3 4 5 Gomaraschi M1, Bonacina F2, Norata GD2,3 6 7 1Center E
    1 LYSOSOMAL ACID LIPASE: FROM CELLULAR LIPID HANDLER TO 2 IMMUNOMETABOLIC TARGET 3 4 5 Gomaraschi M1, Bonacina F2, Norata GD2,3 6 7 1Center E. Grossi Paoletti, Department of Excellence of Pharmacological and Biomolecular 8 Sciences (DisFeB); Università Degli Studi di Milano; Milan, 20133, Italy; 2Department of 9 Excellence of Pharmacological and Biomolecular Sciences (DisFeB); Università Degli Studi di 10 Milano; Milan, 20133, Italy; 3SISA Centre; Bassini Hospital; Cinisello Balsamo, 20092, Italy. 11 12 Corresponding author: 13 Professor Giuseppe Danilo Norata 14 Department of Pharmacological and Biomolecular Sciences (DisFeB); Università Degli Studi 15 di Milano; via Balzaretti 9. Milan, 20133, Italy. 16 Phone: 39 0250318313. Email: [email protected] 17 18 19 20 Keywords 21 Lysosomal acid lipase, cholesterol, fatty acids, immune response, enzyme replacement 22 therapy. 1 23 Abstract 24 Lysosomal acid lipase (LAL) hydrolyzes cholesterol esters and triglycerides to free cholesterol 25 and fatty acids,that are then used for the metabolic purposes in the cell. The process also 26 occurs in immune cells which adapt their metabolic machinery to cope with the different 27 energetic requirements associated to cell activation, proliferation and/or polarization. 28 Deficiency of LAL not only causes severe lipid accumulation, but also impacts the 29 immunometabolic signature in animal models. In humans, LAL deficiency has been recently 30 associated with a peculiar clinical immune phenotype, secondary hemophagocytic 31 lymphohistiocytosis. These observations indicate that LAL represents a critical player for 32 cellular immunometabolic modulation and the availability of an effective enzyme replacement 33 strategy makes LAL an attractive target to rewire the immunometabolic machinery of immune 34 cells beyond its role in controlling cellular lipid metabolism.
    [Show full text]
  • (Asfotase Alfa) and Kanuma™ (Sebelipase Alfa) in the European Union
    Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union June 26, 2015 - CHMP Recommends Marketing Authorization for Strensiq for Patients with Pediatric-Onset HPP - - CHMP Recommends Marketing Authorization for Kanuma for Patients of all Ages with LAL-d - CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending marketing authorization of Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa). The proposed indication for Strensiq is for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. The proposed indication for Kanuma is for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-d). Based on the CHMP's positive recommendations, final decisions from the European Commission are expected in the third quarter of 2015, after which the Company will begin the country-by-country reimbursement processes. Currently, there are no therapies approved for the treatment of HPP or LAL-d. "The CHMP positive opinions for Strensiq and Kanuma are significant milestones in bringing these therapies to infants, children, and adults suffering from HPP and LAL-d in Europe," said David Hallal, Chief Executive Officer of Alexion. "Both Strensiq and Kanuma are highly innovative enzyme replacement therapies that, if approved, will be the first treatments available for patients with HPP and LAL-d, two life-threatening and ultra-rare metabolic disorders." HPP is a genetic, progressive, ultra-rare metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications.
    [Show full text]
  • Sebelipase Alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
    December 8, 2015 FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) - Kanuma is the First Approved Treatment in the United States for Patients Suffering from LAL-D, a Life-threatening and Ultra- rare Metabolic Disorder - - Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET - CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Kanuma™ (sebelipase alfa) for the treatment of patients of all ages with a diagnosis of lysosomal acid lipase deficiency (LAL-D). Kanuma, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with LAL-D, a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151208006282/en/ "We are pleased with the FDA approval of Kanuma, a transformative treatment for patients with LAL-D, a devastating, ultra-rare disease that causes premature death in infants and multi-organ damage in those who survive," said David Hallal, Chief Executive Officer of Alexion. "Importantly, the label includes a survival benefit in infants and reductions in important markers of liver disease, including ALT and liver fat content, as well as significant improvements in lipid parameters, in children and adults. This approval also strengthens Alexion's global leadership in rare diseases as we broaden our product portfolio to transform the lives of more patients with severe and life-threatening disorders.
    [Show full text]
  • Kanuma, INN-Sebelipase Alfa
    25 June 2015 EMA/514387/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Kanuma International non-proprietary name: sebelipase alfa Procedure No. EMEA/H/C/004004/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Manufacturers ..................................................................................................... 7 1.3. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 8 2.1. Introduction ........................................................................................................ 8 2.2. Quality aspects .................................................................................................. 10 2.2.1. Introduction ................................................................................................... 10 2.2.2. Active Substance ............................................................................................
    [Show full text]
  • ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
    MEDS ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 is available in electronic format on the PMPRB website. Une traduction de ce document est également disponible en français sous le titre : Veille des médicaments mis en marché, 2016 Patented Medicine Prices Review Board Standard Life Centre Box L40 333 Laurier Avenue West Suite 1400 Ottawa, ON K1P 1C1 Tel.: 1-877-861-2350 TTY 613-288-9654 Email: [email protected] Web: www.pmprb-cepmb.gc.ca ISSN 2560-6204 Cat. No.: H79-12E-PDF © Her Majesty the Queen in Right of Canada, as represented by the NPDUIS initiative of the Patented Medicine Prices Review Board, 2018 MEDS ENTRY WATCH 2016 About the PMPRB Acknowledgements The Patented Medicine Prices Review Board This report was prepared by the Patented (PMPRB) is a respected public agency that makes Medicine Prices Review Board (PMPRB) a unique and valued contribution to sustainable as part of the National Prescription Drug spending on pharmaceuticals in Canada by: Utilization Information System (NPDUIS). ~ providing stakeholders with price, cost and The PMPRB would like to acknowledge the utilization information to help them make timely contributions of and knowledgeable drug pricing, purchasing and ~ The members of the NPDUIS Advisory reimbursement decisions; and Committee for their expert oversight and ~ acting as an effective check on the patent rights guidance in the preparation of this report. of pharmaceutical manufacturers through the ~ PMPRB NPDUIS staff for their contribution responsible and efficient use of its consumer to the analytical content of the report: protection powers.
    [Show full text]
  • Lists of Medicinal Products for Rare Diseases in Europe*
    March 2021 Lists of medicinal products for rare diseases in Europe* the www.orpha.net www.orphadata.org General Table of contents PART 1: List of orphan medicinal products in Europe with European orphan designation and European marketing authorization 3 Table of contents 3 Methodology 3 Classification by tradename 5 Annex 1: Orphan medicinal products withdrawn from the European Community Register of orphan medicinal products 22 Annex 2: Orphan medicinal products withdrawn from use in the European Union 31 Classification by date of MA in descending order 33 Classification by ATC category 34 Classification by MA holder 35 PART 2 : 37 List of medicinal products intended for rare diseases in Europe with European marketing authorization without an orphan designation in Europe 37 Table of contents 37 Methodology 37 Classification by tradename 38 Classification by date of MA in descending order 104 Classification by ATC category 106 Classification by MA holder 108 For any questions or comments, please contact us: [email protected] Orphanet Report Series - Lists of medicinal products for rare diseases in Europe. March 2021 http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf 2 PART 1: List of orphan medicinal products in Europe with European orphan designation and European marketing authorization* Table of contents List of orphan medicinal products in Europe with European orphan designation and European marketing authorisation* 3 Methodology 3 Classification by tradename 5 Annex 1: Orphan medicinal products removed or withdrawn from the European Community Register of orphan medicinal products 22 Annex 2: Orphan medicinal products withdrawn from use in the European Union 31 Classification by date of MA in descending order 33 Classification by ATC category 34 Classification by MA holder 35 Methodology This part of the document provides the list of all orphan with the list of medicinal products that have been granted a medicinal products that have received a European Marketing marketing authorization (http://ec.europa.
    [Show full text]
  • Clinical Trials, Progression-Speed Differentiating Features, and Swiftness Rule of the Innovative Targets of First-In-Class Drugs
    Supplementary Materials for: Clinical Trials, Progression-speed Differentiating Features, and Swiftness Rule of the Innovative Targets of First-in-class Drugs Ying Hong Li1,2,§, Xiao Xu Li1,2,§, Jia Jun Hong1,§, Yun Xia Wang1,§, Jian Bo Fu1, Hong Yang2, Chun Yan Yu2, Feng Cheng Li1, Jie Hu3, Wei Wei Xue2, Yu Yang Jiang4, Yu Zong Chen5,* & Feng Zhu1,2,* 1 Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China 2 Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing 401331, China 3 School of International Studies, Zhejiang University, Hangzhou 310058, China 4 State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong 518055, China 5 Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore * Corresponding Author: Prof. Feng ZHU, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Tel.: +86-571-88208444; Email: [email protected]; [email protected]. Prof. Yu Zong CHEN, Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore. Tel.: +65-6516- 6877; Email: [email protected] § These authors contributed equally to this work. Ying Hong LI, Xiao Xu LI, Jia Jun HONG and Yun Xia WANG are Ph.D. or master candidates of the College of Pharmaceutical Sciences, Zhejiang University, China. They are interested in bioinformatics and target discovery. Yu Zong CHEN is a professor of Bioinformatic and Drug Design Group (BIDD), Department of Pharmacy, National University of Singapore.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]